TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Misses Estimates By $0.07 EPS

Key Points

• TuHURA Biosciences reported a quarterly earnings loss of ($0.21) EPS, which was $0.07 lower than the expected consensus of ($0.14).
• The company's stock price increased by $0.30 to reach $3.06 following the earnings announcement, with a trading volume of 643,125 shares.
• Several institutional investors have recently adjusted their stakes in TuHURA, including Geode Capital Management, which increased its position by 111.4% during the second quarter.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports.

TuHURA Biosciences Trading Down 2.3%

NASDAQ:HURA traded down $0.07 during trading hours on Thursday, reaching $2.91. The company had a trading volume of 196,273 shares, compared to its average volume of 769,473. The business's 50-day simple moving average is $2.60 and its two-hundred day simple moving average is $3.15. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $8.40.

Wall Street Analyst Weigh In

HURA has been the subject of several recent research reports. Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, July 18th. Brookline Capital Management upgraded shares of TuHURA Biosciences to a "strong-buy" rating in a research report on Monday, June 23rd. Finally, HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of TuHURA Biosciences in a research report on Friday, May 16th. Two research analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $12.67.

Institutional Investors Weigh In On TuHURA Biosciences

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences in the second quarter worth $27,000. Invesco Ltd. bought a new position in shares of TuHURA Biosciences in the second quarter valued at $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of TuHURA Biosciences in the second quarter valued at $31,000. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at $59,000. Finally, Jane Street Group LLC bought a new position in shares of TuHURA Biosciences in the first quarter valued at $69,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.